Read by QxMD icon Read


Wolfgang Roll, Axel Bode, Matthias Weckesser, Martin Bögemann, Kambiz Rahbar
Recently radiolabeled ligands targeting prostate specific membrane antigen (PSMA) have been introduced for diagnostics and treatment of prostate cancer. Labeled with Lutetium, PSMA radioligand therapy (RLT) is one of the most promising new treatments of metastatic castration refractory prostate cancer. We present images of Ga-PSMA PET/CT and parameters of response of a 75-year-old heavily pretreated metastatic castration refractory prostate cancer patient with extended bone metastases, showing an extraordinary biochemical response in PSA-levels concordant to SUV decline in bone metastases...
December 3, 2016: Clinical Nuclear Medicine
Charles R Schmidtlein, James N Turner, Michael O Thompson, Krishna C Mandal, Ida Häggström, Jiahan Zhang, John L Humm, David H Feiglin, Andrzej Krol
Using analytical and Monte Carlo modeling, we explored performance of a lightweight wearable helmet-shaped brain positron emission tomography (PET), or BET camera, based on thin-film digital Geiger avalanche photodiode arrays with Lutetium-yttrium oxyorthosilicate (LYSO) or [Formula: see text] scintillators for imaging in vivo human brain function of freely moving and acting subjects. We investigated a spherical cap BET and cylindrical brain PET (CYL) geometries with 250-mm diameter. We also considered a clinical whole-body (WB) LYSO PET/CT scanner...
January 2017: Journal of Medical Imaging
Sun Il Kwon, Alessandro Ferri, Alberto Gola, Eric Berg, Claudio Piemonte, Simon R Cherry, Emilie Roncali
Current research in the field of positron emission tomography (PET) focuses on improving the sensitivity of the scanner with thicker detectors, extended axial field-of-view, and time-of-flight (TOF) capability. These create the need for depth-of-interaction (DOI) encoding to correct parallax errors. We have proposed a method to encode DOI using phosphor-coated crystals. Our initial work using photomultiplier tubes (PMTs) demonstrated the possibilities of the proposed method, however, a major limitation of PMTs for this application is poor quantum efficiency in yellow light, corresponding to the wavelengths of the converted light by the phosphor coating...
October 2016: Journal of Medical Imaging
Dale L Bailey, Thomas M Hennessy, Kathy P Willowson, E Courtney Henry, David Lh Chan, Alireza Aslani, Paul J Roach
OBJECTIVES: Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as "No Carrier Added" (NCA) (177)Lu. We have radiolabelled DOTA-conjugated peptide DOTA-(Tyr(3))-octreotate with NCA (177)Lu ("NCA-LuTATE") and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on our initial studies on aspects of the biodistribution and dosimetry of NCA-LuTATE from gamma camera 2D whole body (WB) and quantitative 3D SPECT (qSPECT) (177)Lu imaging...
2016: Asia Oceania Journal of Nuclear Medicine & Biology
M M Heck, M Retz, R Tauber, K Knorr, C Kratochwil, M Eiber
Radioligand therapy (RLT) directed against prostate-specific membrane antigen (PSMA) enables tumor-specific treatment directed against PSMA-overexpressing prostate cancer cells. Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with β‑radiating lutetium-177. These are currently applied in compassionate use programs to treat metastatic castration-resistant prostate cancer (mCRPC). PSMA-directed RLT is currently being offered in several nuclear medicine departments throughout Germany...
November 24, 2016: Der Urologe. Ausg. A
Juliano Guerra Sabongi, Mônica Carboni Pereira Gonçalves, Cira Danielle Casado Alves, João Alves, Cristovam Scapulatempo-Neto, Sonia Marta Moriguchi
Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant tumor that accounts for 3% of all tumors of the nasal cavity. The incidence of ENB is 0.4 cases per million in the general population, and the most common symptoms are nasal obstruction and epistaxis. Previous studies have indicated the presence of somatostatin receptors in this tumor type. Common treatment strategies for ENB include resection and adjuvant radiotherapy and/or chemotherapy (combined treatment); however, the rate of recurrence is high...
November 2016: Experimental and Therapeutic Medicine
Yean-Sheng Yong, Shanmugam Aravazhi, Sergio A Vázquez-Córdova, Joan J Carjaval, Francesc Díaz, Jennifer L Herek, Sonia M García-Blanco, Markus Pollnau
We study the spectroscopic properties of thin films of potassium ytterbium gadolinium double tungstates, KYb<sub>0.57</sub>Gd<sub>0.43</sub>(WO<sub>4</sub>)<sub>2</sub>, and potassium ytterbium lutetium double tungstates, KYb<sub>0.76</sub>Lu<sub>0.24</sub>(WO<sub>4</sub>)<sub>2</sub>, specifically at the central absorption line near 981 nm wavelength, which is important for amplifiers and lasers. The absorption cross-section of both thin films is found to be similar to those of bulk potassium rare-earth double tungstates, suggesting that the crystalline layers retain their spectroscopic properties albeit having >50 at...
November 14, 2016: Optics Express
H Al-Sagur, S Komathi, M A Khan, A G Gurek, A Hassan
Herein, we report a scalable synthesis of multifunctional conducting polyacrylic acid (PAA) hydrogel (MFH) integrated with reduced grapheme oxide (rGO), vinyl substituted polyaniline (VS-PANI) and lutetium Phthalocyanine (LuPc2) as three dimensional robust matrix for glucose oxidase (GOx) immobilization (PAA-rGO/VS-PANI/LuPc2/GOx-MFH). We have integrated the multicomponents such as PAA with rGO, and VS-PANI through free radical polymerization using methylene bis-acrylamide, and ammonium persulphate as the cross linker and initiator...
October 19, 2016: Biosensors & Bioelectronics
Daniel Espes, Ramkumar Selvaraju, Irina Velikyan, Martin Krajcovic, Per-Ola Carlsson, Olof Eriksson
BACKGROUND: There is an increasing interest in alternative implantation sites to the liver for islet transplantation. Intramuscular implantation has even been tested clinically. Possibilities to monitor β-cell mass would be of huge importance not only for the understanding of islet engraftment but also for the decision of changing the immunosuppressive regime. We have therefore evaluated the feasibility of quantifying intramuscular β-cell mass using the radiolabeled glucagon like peptide-1 receptor agonist DO3A-VS-Cys(40)-Exendin-4...
August 2016: Transplantation Direct
Bin Wang, Lailai Yan, Wenhua Huo, Qun Lu, Zixi Cheng, Jingxu Zhang, Zhiwen Li
Studies have shown that residents living near rare earth mining areas have high concentrations of rare earth elements (REEs) in their hair. However, the adverse effects of REEs on human health have rarely been the focus of epidemiological studies. The goal of this study was to evaluate the relationship between REEs in hair and the risk of hypertension in housewives. We recruited 398 housewives in Shanxi Province, China, consisting of 163 women with hypertension (cases) and 235 healthy women without hypertension (controls)...
January 2017: Environmental Pollution
Mustafa İlhan, Mete Kaan Ekmekçi, Rıza Gürcan Oraltay, Ali Sadi Başak
Undoped and Nd(3+) doped lutetium niobate phases have been prepared by a conventional solid state reaction method using lutetium acetate and niobium oxide at 1250 °C for 6 h. X-ray diffraction patterns of the 6 mol% Lu3NbO7 sample exhibited a cubic fluorite single phase. Phase structure exhibited interesting crystallization behaviour depending on increasing Nd(3+) concentration which led to a Lu3NbO7 single phase formation during the heat treatment process. SEM investigations were also in agreement with the XRD results...
October 28, 2016: Journal of Fluorescence
Sung-Jin Jung, Seong-Kwan Hong, Oh-Kyong Kwon
A readout integrated circuit (ROIC) using two-step fastest signal identification (FSI) is proposed to reduce the number of input channels of a data acquisition (DAQ) block with a high-channel reduction ratio. The two-step FSI enables the proposed ROIC to filter out useless input signals that arise from scattering and electrical noise without using complex and bulky circuits. In addition, an asynchronous fastest signal identifier and a self-trimmed comparator are proposed to identify the fastest signal without using a high-frequency clock and to reduce misidentification, respectively...
October 20, 2016: Sensors
Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, Uwe Haberkorn, Michael Schäfers, Markus Essler, Richard P Baum, Harshad R Kulkarani, Matthias Schmidt, Peter Bartenstein, Andreas Pfestroff, Ulf Lützen, Marlies Marx, Vikas Prasad, Winfried Brenner, Alexander Heinzel, Juri Ruf, Philipp Tobias Meyer, Martin Heuschkel, Maria Eveslage, Martin Bögemann, Wolfgang Peter Fendler, Bernd Joachim Krause
: (177)Lutetium labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration resistant prostate cancer (mCRPC). Initiated by the German Society of Nuclear Medicine a retrospective multicenter data analysis was started in 2015 to evaluate efficacy and safety of (177)Lu-PSMA-617 in a large cohort of patients. METHODS: 145 patients (median age 73 years, range 43-88) with mCRPC were treated with (177)Lu-PSMA-617 in 12 therapy centres between February 2014 and July 2015 with one to four therapy cycles and an activity range of 2 to 8 GBq per cycle...
October 20, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Oliver Sartor
Radiopharmaceuticals used in the treatment of castrate-resistant prostate cancer are reviewed herein with an emphasis on sequential and combination therapies. Four bone-seeking radiopharmaceuticals had been approved in the United States. Three of these are β-emitters (phosphorus-32, strontium-89, samarium-153-ethylenediaminetetramethylene-phosphonic acid) that are approved for palliative purposes. One α-emitter (radium-223 [Ra]) is approved for prolongation of survival in bone metastatic castrate-resistant prostate cancer...
September 2016: Cancer Journal
Ximena Camacho, Victoria Calzada, Marcelo Fernández, Omar Alonso, Roger Chammas, Eloisa Riva, Juan Pablo Gambini, Pablo Cabral
BACKGROUND: Vascular endothelial growth factor (VEGF) is one of the classic factors to tumor-induced angiogenesis in several types, including melanoma. Bevacizumab is a humanized monoclonal antibody directed against VEGF. OBJECTIVE: To radiolabel Bevacizumab with 177-Lutetium as a potential radioimmunotherapy agent for melanoma. METHODS: Bevacizumab was derivatized with DOTA-NHS-ester at 4 ºC for 18 h. DOTA-Bevacizumab was radiolabeled with 177LuCl3 (15 MBq/mg) at 37 ºC for 1 h...
October 10, 2016: Current Radiopharmaceuticals
Maria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, Rebecca Dumont, Nicolas Marincek, Attila Kollar, Philippe Brunner, Jan Beyersmann, Jan Mueller-Brand, Helmut Maecke, Markus Laimer, Martin Walter
: We aimed to assess the risk of developing diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors (NET). METHODS: NET patients received somatostatin radiopeptide therapy with yttrium-90-DOTATOC and/or lutetium-177-DOTATOC. The incidence of diabetes mellitus and its mortality were assessed using univariate and multivariate regression. RESULTS: Overall, 1535 NET patients were enrolled, and received 3807 treatment cycles...
September 15, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Arturo Olvera Salazar, Margarita García Hernández, Perla Yolanda López Camacho, Arturo López Marure, Adriana Isabel Reyes de la Torre, Ángel de Jesús Morales Ramírez, Felipe Hernández Santiago, Luciano Aguilera Vázquez
This paper presents the synthesis of pure and europium-doped lutetium oxide (Lu2O3) powders prepared by sol-gel method. The influence of europium ion concentration into Lu2O3 nanocrystallites was investigated for first time in an in vitro system using a modified ABTS radical cation decolorization assay to determine the antioxidant activity. The crystalline structure of Lu2O3 and Eu:Lu2O3 powders was elucidated by XRD obtaining cubic phase in all system without secondary products in accordance with FT-IR results...
December 1, 2016: Materials Science & Engineering. C, Materials for Biological Applications
Showkat H Mir, Prakash C Jha, M S Islam, Amitava Banerjee, Wei Luo, Shweta D Dabhi, Prafulla K Jha, R Ahuja
No abstract text is available yet for this article.
2016: Scientific Reports
Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, Maria Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A Dumont, Helmut R Maecke, Jan Müller-Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A Walter
PURPOSE: Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr2) in neuroendocrine tumors (NETs). METHODS: We established a tissue microarray and imaging database from NET patients that received sstr2-targeted radiopeptide therapy with yttrium-90-DOTATOC, lutetium-177-DOTATOC or alternative treatment. We used univariate and multivariate analyses to identify prognostic and predictive markers for overall survival, including sstr2-imaging and sstr2-immunohistochemistry...
August 18, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Tobias Weber, Benedikt Bötticher, Michaela A E Arndt, Walter Mier, Max Sauter, Evelyn Exner, Armin Keller, Susanne Krämer, Karin Leotta, Artjom Wischnjow, Ludger Grosse-Hovest, Dirk Strumberg, Dirk Jäger, Hermann-Josef Gröne, Uwe Haberkorn, Gottfried Brem, Jürgen Krauss
Radioimmunotherapy is considered as treatment option in recurrent and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). To overcome the dose limiting bone marrow toxicity of IgG-based radioimmunoconjugates (RICs), we modified a humanized diabody with 5-, 10-, or 20-kDa polyethylene glycol (PEG) for CD22-targeted radioimmunotherapy using the low-energy β-emitter lutetium-177 ((177)Lu). A favorable pharmacokinetic profile was observed for the 10-kDa-PEG-diabody in nude mice being xenografted with subcutaneous human Burkitt lymphoma...
October 28, 2016: Cancer Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"